Refractory Gout

Introduction

If you are reading this, you or someone close to you has probably been living with gout for a while, and the usual treatment has not been working as well as expected. Maybe flares keep coming back. Maybe lumps called tophi have appeared under the skin. Maybe your uric acid level refuses to come down even though you have been taking medication. This is what doctors call refractory gout — gout that has become difficult to control with standard therapy.

Refractory gout is uncommon compared to ordinary gout, but it is a recognised clinical situation with its own set of treatment strategies. The good news is that even when first-line tablets are not enough, rheumatologists today have several further options to lower uric acid, dissolve crystal deposits, and protect the joints from further damage.

This guide explains what refractory gout is, why it develops, how it is diagnosed, what treatment options are available, and what daily life with the condition usually looks like. It is written for people who already have a diagnosis or are being assessed for refractory disease, and who want to understand the road ahead.

What Is Refractory Gout?

Gout is a form of inflammatory arthritis caused by high levels of uric acid (also called urate) in the blood. When uric acid levels stay high for a long time, the body forms sharp crystals that settle in joints and surrounding tissues. These crystals trigger sudden, very painful attacks of joint inflammation, called flares or gout attacks.

In most people, gout responds well to a combination of:

• Medication to lower uric acid in the blood (called urate-lowering therapy)
• Medication to settle the inflammation of a flare
• Changes to diet, alcohol intake, weight, and other lifestyle factors

Refractory gout is the term used when this standard approach does not bring the disease under control. There is no single worldwide definition, but rheumatologists generally use the term when one or more of the following is true despite appropriate treatment:

• Serum uric acid remains above the target level (commonly less than 6 mg/dL, and often less than 5 mg/dL when tophi are present)
• Flares continue to occur frequently
• Tophi (visible or palpable urate deposits under the skin or around joints) persist or grow
• Joint damage or deformity is progressing
• The person cannot tolerate standard urate-lowering medications at the doses needed to control the disease

Refractory gout is sometimes also called uncontrolled gout, severe tophaceous gout, or treatment-resistant gout. These terms overlap and are usually used to describe the same broad clinical picture.

It is important to understand that refractory gout is not a sign of personal failure. It usually reflects a combination of biology (how the body handles uric acid), the presence of other medical conditions, and the practical challenges of long-term medication use.

Causes and Risk Factors

Several different factors can push gout from a manageable condition into a refractory one. Often, more than one factor is at work.

Long-standing high uric acid

When uric acid has been high for many years before treatment begins, the body builds up a large “reservoir” of urate crystals in joints and tissues. Dissolving this reservoir takes time, and during this period flares can still occur. People who were diagnosed late, or whose uric acid was never measured for years, often have a larger crystal burden to clear.

Kidney disease

The kidneys are the body’s main route for clearing uric acid. When kidney function is reduced — from chronic kidney disease, diabetes, high blood pressure, or other causes — uric acid builds up more easily. Kidney disease also limits the choice and dose of some gout medications, making control harder.

Medication intolerance

Some people develop side effects from first-line urate-lowering medications such as allopurinol or febuxostat — for example, skin rash, gastrointestinal upset, or changes in liver tests. Others may have had a serious reaction such as hypersensitivity to allopurinol. When standard medications cannot be used at full dose, uric acid is harder to bring into the target range.

Drug interactions and other medications

Some commonly used medications raise uric acid as a side effect, including certain diuretics (water tablets) used for blood pressure or heart failure, low-dose aspirin, and some immunosuppressants used after organ transplant. When these drugs are necessary for other conditions, controlling gout becomes more complex.

Genetic factors

How efficiently the kidneys excrete uric acid is partly genetic. Some people have inherited variations that make them produce more urate or excrete less of it. These differences help explain why some people develop severe gout even with a careful diet.

Lifestyle contributors

Diet and lifestyle alone do not usually cause refractory gout, but they can make control harder. Common contributors include:

• High intake of red meat, organ meats, and shellfish
• Sugary drinks, especially those sweetened with fructose
• Regular alcohol use, particularly beer and spirits
• Obesity and metabolic syndrome
• Inactivity

Adherence and access

Urate-lowering therapy works only when it is taken every day, for life. Stopping medication during periods when joints feel fine, or stopping during a flare in the mistaken belief that the medicine is causing the attack, are common reasons why uric acid stays high. Difficulty getting regular follow-up and blood tests can also contribute.

Signs and Symptoms of Refractory Disease

You probably already know the basic symptoms of a gout flare: sudden severe pain, swelling, redness, and warmth in a joint, often the big toe but also the ankle, knee, elbow, wrist, or fingers. The features that suggest gout has become refractory tend to develop over months and years rather than overnight.

Frequent flares

More than two flares a year while on urate-lowering therapy is one of the signals that current treatment is not enough. Some people with refractory gout experience flares every few weeks.

Chronic joint discomfort between flares

In well-controlled gout, joints usually feel normal between attacks. In refractory disease, joints can ache, swell, or stiffen even when no flare is active. Movement may become limited.

Tophi

Tophi are firm lumps of urate crystals that form under the skin, around joints, on the ear, over the elbow, or on the fingers and toes. They can be small or large. Sometimes they ulcerate and discharge a chalky white material. Tophi indicate a heavy crystal burden and almost always mean that more aggressive urate-lowering treatment is needed.

Joint deformity and reduced mobility

Long-standing refractory gout can damage cartilage and bone, leading to visibly deformed fingers or toes, restricted movement, and difficulty with daily tasks such as walking, gripping, or wearing shoes.

Kidney symptoms

If your doctor suspects refractory gout, the assessment usually involves three things: confirming that the joint problem is truly gout, measuring how active the disease is, and identifying any factors making control difficult.

Reviewing your treatment history

Your rheumatologist will go through:

• What urate-lowering medications you have taken, at what doses, and for how long
• How well you have been able to take them
• Any side effects you have experienced
• Your serum uric acid readings over time
• How often flares have been occurring
• Other medical conditions and medications

Blood tests

Common tests include:

• Serum uric acid level
• Kidney function tests (creatinine, eGFR)
• Liver function tests
• Full blood count
• Markers of inflammation (such as CRP and ESR), especially during a flare
• Cardiovascular risk markers, since gout is linked with heart and kidney disease

Joint fluid analysis

When there is doubt about the diagnosis, fluid is drawn from an affected joint with a fine needle and examined under a special microscope. Seeing urate crystals confirms gout. This test is especially useful when joint infection is also a possibility, as gout and infection can sometimes look similar.

Imaging

Several types of imaging help assess crystal burden and joint damage:

• X-rays show joint damage and bone erosion in long-standing disease
• Ultrasound can detect urate deposits in joints and tendons
• Dual-energy CT (DECT) is a specialised scan that highlights urate deposits in the body and can map their extent. It is particularly useful in refractory or tophaceous disease.

Testing before pegloticase

If pegloticase (an advanced infusion therapy described later) is being considered, your doctor will typically order a blood test for G6PD deficiency, an inherited enzyme condition. Pegloticase is not safe in people with G6PD deficiency, so this is checked first.

Treatment Goals

The American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) both publish guidelines on gout management. Their treatment goals for refractory disease are broadly consistent:

1. Lower serum uric acid to a target level — generally below 6 mg/dL, and below 5 mg/dL when tophi or severe disease are present — and keep it there long-term
2. Reduce the frequency and severity of flares
3. Dissolve existing urate crystals, including tophi
4. Protect joints from further damage and preserve function
5. Treat associated conditions such as kidney disease, high blood pressure, and cardiovascular risk factors

Medication is at the centre of refractory gout management. Most treatment plans combine medicines to lower uric acid with medicines to control flares while the body adjusts.

Optimising first-line urate-lowering therapy

Before moving to advanced therapy, rheumatologists usually try to make sure that standard medications have been used to their full potential.

Allopurinol is the most widely used urate-lowering drug worldwide. It works by reducing how much uric acid the body makes. In many people with apparent refractory gout, allopurinol has actually only been tried at low or moderate doses. ACR guidance supports gradually increasing the dose — sometimes well above the starting dose — until the uric acid target is reached, provided the patient tolerates it and kidney function allows. Dose increases are made slowly with regular monitoring.

Febuxostat works in a similar way to allopurinol and is an option for people who cannot tolerate allopurinol or who have not reached target on it. Febuxostat does not need dose adjustment in mild to moderate kidney disease, which makes it useful in some patients. Cardiovascular history is taken into account before starting it.

Uricosuric medications

Uricosurics increase the amount of uric acid the kidneys remove. They can be added to a xanthine oxidase inhibitor (allopurinol or febuxostat) when target is not reached on monotherapy.

Probenecid is the most established uricosuric. It is typically used in people whose kidney function is reasonably well preserved and who do not have a history of uric acid kidney stones. Other uricosurics, such as benzbromarone, are available in some countries.

Pegloticase: advanced infusion therapy

For people with severe refractory or tophaceous gout in whom oral medications have failed or cannot be used, pegloticase is an option supported by ACR and EULAR guidance.

Important features of pegloticase therapy:

• It can lower uric acid dramatically and shrink tophi over months
• G6PD deficiency must be excluded before starting
• Infusion reactions can occur; pre-medication with antihistamines and steroids is standard
• Uric acid is measured before each infusion. A rising level suggests the body is forming antibodies against the drug, which makes further infusions less effective and increases the risk of reactions. In that situation, treatment is usually stopped.
• Recent evidence supports combining pegloticase with an immunosuppressant such as methotrexate to reduce antibody formation and improve response rates. This combination is increasingly used.

Pegloticase is generally given for a defined period to clear the urate burden, after which patients are usually returned to oral urate-lowering therapy for long-term maintenance.

Medications for flares

Flares can still happen during treatment, especially in the first months of urate-lowering therapy, when crystals begin to dissolve and shift. Several options are used to manage flares:

• NSAIDs (non-steroidal anti-inflammatory drugs) such as naproxen or indomethacin
• Colchicine, particularly effective if started early in a flare
• Corticosteroids, taken by mouth, injected into a joint, or given as a short course
• Interleukin-1 inhibitors (such as anakinra or canakinumab) for people who cannot use NSAIDs, colchicine, or steroids, or who have flares that do not settle with these

The choice depends on kidney function, heart disease, diabetes, infection risk, and other medical conditions.

Flare prevention during the early months

When urate-lowering therapy is started or its dose is increased, flares often become more frequent for several months before settling. To prevent this, rheumatologists commonly prescribe a low daily dose of colchicine, an NSAID, or a low dose of a steroid for the first three to six months. This “prophylaxis” is an important part of treatment, even though it can feel counter-intuitive to take a daily medicine to prevent attacks while another medicine appears to be triggering them.

Why urate-lowering therapy should not be stopped during a flare

A common mistake is to stop allopurinol, febuxostat, or other urate-lowering drugs during a flare. Stopping can actually prolong the flare and worsen control over time. Current guidelines advise continuing urate-lowering therapy through the flare unless your doctor specifically tells you otherwise.

Lifestyle and Non-Medication Management

Lifestyle changes do not replace medication in refractory gout, but they can meaningfully support it.

Diet

No diet can lower uric acid as much as effective medication, but certain food and drink patterns help. General guidance supported by rheumatology societies includes:

Limit or reduce:

• Red meat and organ meats (liver, kidney, brain)
• Shellfish and some oily fish in large quantities
• Sugary drinks, especially those with high-fructose corn syrup
• Beer and spirits; wine in moderation

Include more of:

• Water and other unsweetened fluids, to keep well hydrated
• Low-fat dairy products, which appear to be associated with lower uric acid
• Vegetables, including those once thought to be off-limits such as spinach and mushrooms — current evidence does not link vegetable purines to gout flares in the same way as meat purines
• Whole grains, legumes, nuts
• Cherries, which some studies suggest may be associated with fewer flares, although they should not replace medication

Weight

Excess weight is linked with higher uric acid and more gout flares. Gradual weight loss, when appropriate, is associated with lower urate levels. Rapid weight loss or fasting can temporarily raise uric acid and trigger flares, so a steady, supervised approach is preferred.

Physical activity

Low-impact activity such as walking, swimming, cycling, or gentle strength training helps with weight, cardiovascular health, and joint mobility. During an active flare, the affected joint should be rested.

Alcohol

Beer is particularly associated with flares because it contains both alcohol and purines. Spirits also raise risk. Cutting alcohol back significantly — or stopping it altogether — is often one of the most impactful changes people can make.

Reviewing other medications

Some medicines used for high blood pressure, heart failure, or transplant care can raise uric acid. If you take such medicines, your doctors may consider whether alternatives are suitable for your overall condition. Do not change these medicines on your own.

Looking after the whole person

Chronic pain, visible tophi, and limited mobility can affect mood, sleep, work, and relationships. Talking openly with your doctor about how the condition is affecting daily life, and accessing support such as physiotherapy, occupational therapy, or counselling when needed, is a recognised part of long-term care.

Monitoring and Follow-up

Refractory gout is a long-term condition, and regular follow-up is part of keeping it controlled.

Typical monitoring includes:

• Serum uric acid every 1 to 3 months while the dose of urate-lowering therapy is being adjusted, then every 6 to 12 months once stable
• Kidney and liver function tests at intervals decided by your rheumatologist
• Review of flare frequency and severity
• Examination of tophi to assess whether they are shrinking
• Discussion of side effects and any difficulties with medication
• Blood pressure, blood sugar, and cholesterol checks, given the link between gout and cardiovascular disease

Reaching the target uric acid level is not the end of treatment. Urate-lowering therapy is usually continued indefinitely, because stopping it almost always leads to uric acid rising again and crystals re-forming.

Managing Flares

Even with well-managed refractory gout, occasional flares can still occur, particularly during the first year or two of intensive treatment. Practical points that help:

• Treat flares early. The sooner anti-inflammatory medication is started, the shorter the flare tends to be.
• Keep an agreed flare plan with your rheumatologist, so you know what to take, in what dose, and for how long.
• Rest the joint, use cold packs if helpful, and keep the limb elevated.
• Stay hydrated.
• Continue your urate-lowering therapy unless specifically told to stop it.
• Contact your doctor if a flare is severe, involves multiple joints, comes with fever, or does not settle within a few days, as joint infection should be ruled out.

Living with Refractory Gout

Refractory gout can be demanding. Pain, swelling, and reduced mobility can interfere with work, sleep, exercise, and family life. Visible tophi can affect confidence. Frequent appointments and tests take time. The chronic nature of the condition can be discouraging.

With consistent treatment, most people see meaningful change over time:

• Flares become less frequent and less severe
• Tophi gradually shrink, sometimes over years
• Joint pain between flares decreases
• Mobility and quality of life improve
• The risk of further joint damage falls

Patience matters. Urate-lowering therapy works slowly, and the body needs time to dissolve crystal deposits that may have been building up for years.

Practical adaptations

Depending on which joints are affected, simple adaptations can make daily life easier:

• Wide, soft, supportive footwear if feet are involved
• Walking aids during flares
• Adjustments at work to reduce time on the feet or repetitive joint strain
• Physiotherapy and tailored exercise to maintain strength and range of motion
• Occupational therapy for hand involvement, including grip aids and joint protection techniques

Emotional health

Chronic pain and visible disease can affect mood. It is reasonable to discuss low mood, anxiety, or sleep problems with your doctor. Treating these alongside the physical condition often improves overall outcomes.

Complications

If refractory gout is not brought under control, complications can develop over time:

• Joint damage and deformity from ongoing inflammation and tophus formation
• Chronic kidney disease, which may both contribute to and result from long-standing high uric acid
• Uric acid kidney stones
• Cardiovascular disease, which is more common in people with gout and which contributes to long-term risk
• Infected tophi, particularly when they ulcerate through the skin
• Reduced quality of life from pain, disability, and the demands of frequent treatment

These complications are the reason rheumatologists are willing to use stronger treatments such as pegloticase in selected patients: the risks of uncontrolled disease are not small.

When to Seek Urgent Care

While refractory gout is generally managed in the clinic rather than in emergency settings, certain situations need prompt attention:

• A hot, swollen joint with fever or feeling unwell — joint infection must be ruled out
• A tophus that has opened, is discharging, or appears infected
• Severe flank pain, blood in the urine, or other signs that may suggest kidney stones
• A sudden reduction in urine output
• Severe rash, mouth sores, or fever after starting allopurinol or febuxostat, which can suggest a serious drug reaction
• Severe reaction during or shortly after an infusion of pegloticase

When in doubt, contact your rheumatology team or seek medical attention.

Long-term Outlook

Refractory gout used to be a deeply disabling condition for many people. Today, with optimised oral therapy, the addition of uricosurics when appropriate, and the option of pegloticase for the most severe cases, long-term control is achievable for the majority of patients who can engage with a structured plan.

Key points to keep in mind about the long-term picture:

• Treatment is lifelong. Urate-lowering therapy is usually continued indefinitely.
• Reaching the target uric acid level is the single most important determinant of long-term control.
• Tophi can take months to years to dissolve, even with effective treatment.
• Looking after kidney health, blood pressure, weight, and cardiovascular risk is part of long-term care.
• Regular follow-up with a rheumatologist is the usual model of care.

Frequently Asked Questions

What does “refractory” really mean in my case?

It usually means that despite taking standard gout medication, your uric acid is not at target, you are still having frequent flares, you have tophi, or you cannot tolerate the doses needed. The specific definition your rheumatologist uses will depend on your history, your blood tests, and your examination.

Can refractory gout be cured?

Gout is a long-term condition and is not cured in the strict sense, but it can be very effectively controlled. With sustained treatment, flares can become rare, tophi can shrink, and joint function can be preserved.

Is pegloticase right for everyone with refractory gout?

No. Pegloticase is reserved for people with severe disease who have not responded to oral medications or who cannot use them. It is not used in people with G6PD deficiency. Whether it is appropriate is a clinical decision made by your rheumatologist after a full assessment.

Will my tophi go away?

Tophi can shrink and even disappear with sustained, effective urate lowering, but the process is usually slow — often months to years. The lower and more consistent your uric acid level, the better the chance of significant tophus reduction.

Should I stop my gout medication during a flare?

Generally, no. Current professional guidelines advise continuing urate-lowering therapy through a flare unless your own doctor tells you otherwise. Flare medication is added on top to settle the inflammation.

Do I need to change my diet completely?

Strict diets alone do not control refractory gout. Most rheumatologists focus on a few high-impact changes: reducing red meat and organ meats, limiting sugary drinks, cutting back on alcohol (especially beer), staying well hydrated, and including more vegetables, low-fat dairy, and whole grains. Working with a dietitian can help tailor this to your situation.

Is gout linked to other health problems?

Yes. Gout is associated with high blood pressure, kidney disease, diabetes, obesity, and cardiovascular disease. This is why long-term gout care usually includes attention to these conditions as well.

Why do I keep getting flares even though my uric acid is normal now?

When uric acid first comes down, crystals that have been sitting in joints for years begin to dissolve and shift. This can trigger flares for several months. Most rheumatologists prescribe a daily anti-inflammatory medicine during this period to prevent these “mobilisation” flares. Over time, as the crystal burden clears, flares become much less frequent.

Can I drink any alcohol at all?

This depends on your overall health and how active your gout is. Beer and spirits are most strongly associated with flares. Wine in modest amounts is less strongly linked but is not risk-free. Many people with refractory gout find that significantly reducing or stopping alcohol makes a noticeable difference.

How often will I need to see a rheumatologist?

While treatment is being adjusted, visits and blood tests are often every 1 to 3 months. Once your uric acid is stable at target and flares are well controlled, follow-up may move to every 6 to 12 months. People on pegloticase are seen more frequently because infusions are typically given every two weeks.

Conclusion

Refractory gout is a more complex and persistent form of an already painful condition, but it is not untreatable. By moving beyond standard doses, combining therapies, and using advanced options such as pegloticase in selected patients, rheumatologists today can bring even severe, long-standing gout under control.

The core principles are simple, even when the medicine is complex: get uric acid below target, keep it there for the long term, treat flares promptly, support the joints and the rest of the body, and stay in regular contact with your care team. With time and consistency, most people with refractory gout see meaningful improvement in pain, mobility, and daily life.